Authors:
Tinger, A
Waldron, T
Peluso, N
Katin, NJ
Dosoretz, DE
Blitzer, PH
Rubenstein, JH
Garton, GR
Nakfoor, BA
Patrice, SJ
Chuang, L
Orr, JW
Citation: A. Tinger et al., Effective palliative radiation therapy in advanced and recurrent ovarian carcinoma, INT J RAD O, 51(5), 2001, pp. 1256-1263
Citation: T. Waldron, Are all SSRIs created equal? The competition is heated in the antidepressant market. So how's a perplexed prescriber to choose, BEHAV HEALT, 9(4), 2000, pp. 33-36
Authors:
Murugesan, N
Gu, ZX
Stein, PD
Spergel, S
Mathur, A
Leith, L
Liu, ECK
Zhang, RA
Bird, E
Waldron, T
Marino, A
Morrison, RA
Webb, ML
Moreland, S
Barrish, JC
Citation: N. Murugesan et al., Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4 '-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ETAantagonists, J MED CHEM, 43(16), 2000, pp. 3111-3117
Authors:
Robinson, TC
Tobet, SA
Chase, C
Waldron, T
Sower, SA
Citation: Tc. Robinson et al., Gonadotropin-releasing hormones in the brain and pituitary of the teleost,the white sucker, GEN C ENDOC, 117(3), 2000, pp. 381-394
Citation: T. Waldron, Managed care's atypical response - New antipsychotics show promise, but are they getting into enough hands?, BEHAV HEALT, 8(2), 1999, pp. 28-31
Citation: T. Waldron, 'Low-grade' depression - Primary care physicians need a crash course in detection and treatment, BEHAV HEALT, 8(2), 1999, pp. 32-35
Citation: B. Tesfamariam et al., Quantitation of tremor in response to beta-adrenergic receptor stimulationin primates: Relationship with hypokalemia, J PHARM TOX, 40(4), 1998, pp. 201-205
Authors:
Murugesan, N
Gu, ZX
Stein, PD
Bisaha, S
Spergel, S
Girotra, R
Lee, VG
Lloyd, J
Misra, RN
Schmidt, J
Mathur, A
Stratton, L
Kelly, YF
Bird, E
Waldron, T
Liu, ECK
Zhang, RG
Lee, H
Serafino, R
Abboa-Offei, B
Mathers, P
Giancarli, M
Seymour, AA
Webb, ML
Moreland, S
Barrish, JC
Hunt, JT
Citation: N. Murugesan et al., Biphenylsulfonamide endothelin antagonists: Structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of theorally active endothelin antagonist 2 '-amino-N-(3,4-dimethyl-5-isoxazolyl)-4 '-(2-methylpropyl)[1,1 '-biphenyl]-2-sulfonamide (BMS-187308), J MED CHEM, 41(26), 1998, pp. 5198-5218